603127 昭衍新药
午间休市 08-14 11:29:59
资讯
新帖
简况
昭衍新药：低价订单正在有序出清
证券之星 · 08-12 17:39
昭衍新药：低价订单正在有序出清
昭衍新药：截至2026年一季度末在手订单金额为31亿元人民币
证券之星 · 08-12 16:57
昭衍新药：截至2026年一季度末在手订单金额为31亿元人民币
每周股票复盘：昭衍新药（603127）A股限制性股票激励计划完成授予
证券之星 · 08-09
每周股票复盘：昭衍新药（603127）A股限制性股票激励计划完成授予
8月7日昭衍新药涨10.01%，广发医疗保健股票A基金重仓该股
证券之星 · 08-07
8月7日昭衍新药涨10.01%，广发医疗保健股票A基金重仓该股
港股异动 | 昭衍新药(06127)涨超11% 公司上半年业绩大幅预增 生物资产公允价值正向变动成为核心驱动力
智通财经 · 08-07
港股异动 | 昭衍新药(06127)涨超11% 公司上半年业绩大幅预增 生物资产公允价值正向变动成为核心驱动力
异动快报：昭衍新药（603127）8月7日14点7分触及涨停板
证券之星 · 08-07
异动快报：昭衍新药（603127）8月7日14点7分触及涨停板
昭衍新药（603127）披露2026年A股限制性股票激励计划授予完成情况，8月5日股价上涨4.4%
证券之星 · 08-05
昭衍新药（603127）披露2026年A股限制性股票激励计划授予完成情况，8月5日股价上涨4.4%
8月4日昭衍新药涨8.04%，广发医疗保健股票A基金重仓该股
证券之星 · 08-04
8月4日昭衍新药涨8.04%，广发医疗保健股票A基金重仓该股
港股开盘 | 恒指高开0.31% 医药CXO板块走强 药明康德(02359)涨近10%、中际旭创(03308)涨超9%
智通财经 · 08-04
港股开盘 | 恒指高开0.31% 医药CXO板块走强 药明康德(02359)涨近10%、中际旭创(03308)涨超9%
医药外包概念整体回暖 昭衍新药（06127）涨4.51%、康龙化成（03759）涨3.10%
金吾财讯 · 07-31
医药外包概念整体回暖 昭衍新药（06127）涨4.51%、康龙化成（03759）涨3.10%
昭衍新药：非人灵长类实验动物存栏属于公司经营核心运营数据
证券之星 · 07-30
昭衍新药：非人灵长类实验动物存栏属于公司经营核心运营数据
7月30日昭衍新药跌8.85%，广发医疗保健股票A基金重仓该股
证券之星 · 07-30
7月30日昭衍新药跌8.85%，广发医疗保健股票A基金重仓该股
7月28日昭衍新药跌8.31%，广发医疗保健股票A基金重仓该股
证券之星 · 07-28
7月28日昭衍新药跌8.31%，广发医疗保健股票A基金重仓该股
医药外包概念全线扬升 昭衍新药(06127)涨7.93% 机构指CXO景气进入中报业绩兑现期
金吾财讯 · 07-27
医药外包概念全线扬升 昭衍新药(06127)涨7.93% 机构指CXO景气进入中报业绩兑现期
异动快报：昭衍新药（603127）7月27日10点2分触及涨停板
证券之星 · 07-27
异动快报：昭衍新药（603127）7月27日10点2分触及涨停板
每周股票复盘：昭衍新药（603127）完成263.63万股限制性股票授予
证券之星 · 07-26
每周股票复盘：昭衍新药（603127）完成263.63万股限制性股票授予
7月24日昭衍新药跌6.66%，广发医疗保健股票A基金重仓该股
证券之星 · 07-24
7月24日昭衍新药跌6.66%，广发医疗保健股票A基金重仓该股
昭衍新药（603127）披露2026年A股限制性股票激励计划授予结果公告，7月23日股价上涨0.89%
证券之星 · 07-23
昭衍新药（603127）披露2026年A股限制性股票激励计划授予结果公告，7月23日股价上涨0.89%
昭衍新药（603127）披露完成股份性质变更暨2026年A股限制性股票激励计划实施进展，7月20日股价下跌1.94%
证券之星 · 07-20
昭衍新药（603127）披露完成股份性质变更暨2026年A股限制性股票激励计划实施进展，7月20日股价下跌1.94%
Barclays PLC增持昭衍新药(06127)约327.98万股 每股作价约24.25港元
智通财经 · 07-20
Barclays PLC增持昭衍新药(06127)约327.98万股 每股作价约24.25港元
暂无数据
公司概况
公司名称：
北京昭衍新药研究中心股份有限公司
所属行业：
研究和试验发展
上市日期：
2017-08-25
主营业务：
北京昭衍新药研究中心股份有限公司的主营业务是以药物非临床安全性评价服务为主的药物临床前研究服务和实验动物及附属产品的销售业务。公司的主要产品或服务是药物非临床研究服务、临床服务及其他、实验模型供应。公司同时具备中国NMPA、美国FDA、经合组织OECD、韩国MFDS、日本PMDA等GLP资质；2025年9月公司北京及太仓设施通过了OECD的GLP现场检查及复查。
发行价格：
12.51
{"stockData":{"symbol":"603127","market":"SH","secType":"STK","nameCN":"昭衍新药","latestPrice":50.51,"timestamp":1786678199000,"preClose":51.9,"halted":0,"volume":27061146,"delay":0,"changeRate":-0.0268,"floatShares":628000000,"shares":749000000,"eps":0.6607,"marketStatus":"午间休市","change":-1.39,"latestTime":"08-14 11:29:59","open":51,"high":52.11,"low":49.95,"amount":1383000000,"amplitude":0.0416,"askPrice":50.51,"askSize":4,"bidPrice":50.45,"bidSize":3,"shortable":0,"etf":0,"ttmEps":0.6607,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786683600000},"marketStatusCode":3,"adr":0,"adjPreClose":51.9,"symbolType":"stock","openAndCloseTimeList":[[1786671000000,1786678200000],[1786683600000,1786690800000]],"highLimit":57.09,"lowLimit":46.71,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":749348220,"isCdr":false,"pbRate":4.55,"roa":"--","peRate":76.449221,"roe":"2.82%","epsLYR":0.4,"committee":0.456311,"marketValue":37850000000,"turnoverRate":0.0431,"status":1,"hkstockBrief":{"symbol":"06127","market":"HK","secType":"STK","nameCN":"昭衍新药","latestPrice":24.94,"timestamp":1786678239012,"preClose":25.36,"halted":0,"volume":2285900,"delay":0,"premium":"-57.55"},"floatMarketCap":31706000000},"requestUrl":"/m/hq/s/603127/tweets","defaultTab":"tweets","newsList":[{"id":"2658753589","title":"昭衍新药：低价订单正在有序出清","url":"https://stock-news.laohu8.com/highlight/detail?id=2658753589","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658753589?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:39","pubTimestamp":1786527545,"startTime":"0","endTime":"0","summary":"证券之星消息，昭衍新药08月12日在投资者关系平台上答复投资者关心的问题。低价订单方面，自 2025 年四季度行业回暖、新单量价修复以来，前期存量低价订单正在有序出清。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200030931.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","BK0216","06127","BK1576","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658978431","title":"昭衍新药：截至2026年一季度末在手订单金额为31亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2658978431","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658978431?lang=zh_cn&edition=full","pubTime":"2026-08-12 16:57","pubTimestamp":1786525037,"startTime":"0","endTime":"0","summary":"证券之星消息，昭衍新药(603127)08月12日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，请问贵公司在手订单、项目排期情况如何？实验动物相关价格和订单如何？昭衍新药回复：您好！截至 2026 年一季度末，公司在手订单金额为 31 亿元人民币。伴随生物医药行业需求企稳回暖，现有订单形成一定的交付排期，叠加行业景气度修复，非人灵长类实验动物价格和订单签约价格相较前期都有所回升。感谢关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200028146.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","06127","BK1141","CYB","MUCmain","603127","BK0216","UCmain","MCNHmain","CNHmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658735466","title":"每周股票复盘：昭衍新药（603127）A股限制性股票激励计划完成授予","url":"https://stock-news.laohu8.com/highlight/detail?id=2658735466","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658735466?lang=zh_cn&edition=full","pubTime":"2026-08-09 01:05","pubTimestamp":1786208712,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，昭衍新药报收于50.89元，较上周的41.54元上涨22.51%。本周关注点公司公告汇总：2026年A股限制性股票激励计划于7月22日完成授予，A股已发行股份增加2,636,300股。公司公告汇总H股公告：7月月报表北京昭衍新药研究中心股份有限公司截至2026年7月31日的证券变动月报表显示，H股和A股的法定注册资本无变动。本月底已发行A股总数为630,353,014股，其中库存股为537,620股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000035.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","399300","603127","BK0216","BK1576","06127","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657961579","title":"8月7日昭衍新药涨10.01%，广发医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657961579","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657961579?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:37","pubTimestamp":1786091852,"startTime":"0","endTime":"0","summary":"证券之星消息，8月7日昭衍新药涨10.01%，收盘报50.89元，换手率9.48%，成交量59.53万手，成交额28.88亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共40家，其中持有数量最多的公募基金为广发基金的广发医疗保健股票A。广发医疗保健股票A目前规模为35.24亿元，最新净值1.8412，较上一交易日下跌0.3%，近一年下跌11.34%。广发医疗保健股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700027893.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","603127","BK1141","BK1576","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657818618","title":"港股异动 | 昭衍新药(06127)涨超11% 公司上半年业绩大幅预增 生物资产公允价值正向变动成为核心驱动力","url":"https://stock-news.laohu8.com/highlight/detail?id=2657818618","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657818618?lang=zh_cn&edition=full","pubTime":"2026-08-07 15:20","pubTimestamp":1786087248,"startTime":"0","endTime":"0","summary":"消息面上，近期，昭衍新药发布2026半年度业绩预告，中邮证券指出，2026年上半年，公司预计实现营业收入约6.69亿元至7.39亿元，实现归母净利润约6.00亿元至9.00亿元，实现扣非归母净利润约5.61亿元至8.42亿元。中邮证券认为，生物资产公允价值正向变动成为昭衍新药本期业绩爆发的核心驱动力。2026H1公司生物资产公允价值变动贡献的净利润约7.03亿元至7.77亿元，较2025年同期的0.88亿元大幅提升。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","BK1141","BK4585","BK4588","VXUS","06127","BK1576","603127","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657589694","title":"异动快报：昭衍新药（603127）8月7日14点7分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2657589694","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657589694?lang=zh_cn&edition=full","pubTime":"2026-08-07 14:10","pubTimestamp":1786083046,"startTime":"0","endTime":"0","summary":"证券之星8月7日盘中消息，14点7分昭衍新药（603127）触及涨停板。其所属行业医疗服务目前上涨。领涨股为博腾股份。该股为基因编辑，CAR-T疗法，创新药概念热股，当日基因编辑概念上涨6.16%，CAR-T疗法概念上涨5.68%，创新药概念上涨5.52%。8月6日的资金流向数据方面，主力资金净流入4704.0万元，占总成交额2.34%，游资资金净流出8636.49万元，占总成交额4.29%，散户资金净流入3932.48万元，占总成交额1.95%。近5日资金流向一览见下表：昭衍新药主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700020312.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06127","BK1141","BK1576","BK0216","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657281645","title":"昭衍新药（603127）披露2026年A股限制性股票激励计划授予完成情况，8月5日股价上涨4.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657281645","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657281645?lang=zh_cn&edition=full","pubTime":"2026-08-05 22:04","pubTimestamp":1785938665,"startTime":"0","endTime":"0","summary":"截至2026年8月5日收盘，昭衍新药报收于46.3元，较前一交易日上涨4.4%，最新总市值为346.95亿元。近日，公司披露H股公告《7月月报表》。公告显示，北京昭衍新药研究中心股份有限公司截至2026年7月31日的证券变动月报表显示，H股和A股的法定注册资本无变动。A股已发行股份因2026年A股限制性股票激励计划于2026年7月22日授予，导致已发行股份增加2,636,300股，库存股相应减少2,636,300股。本月底已发行A股总数为630,353,014股，其中库存股为537,620股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500043043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","399300","BK0216","BK1141","06127","159982","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656365725","title":"8月4日昭衍新药涨8.04%，广发医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2656365725","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656365725?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:35","pubTimestamp":1785832545,"startTime":"0","endTime":"0","summary":"证券之星消息，8月4日昭衍新药涨8.04%，收盘报44.35元，换手率9.81%，成交量61.56万手，成交额26.96亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共40家，其中持有数量最多的公募基金为广发基金的广发医疗保健股票A。广发医疗保健股票A目前规模为35.24亿元，最新净值1.7486，较上一交易日下跌2.18%，近一年下跌16.94%。广发医疗保健股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400027511.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","BK1141","BK1576","603127","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656816586","title":"港股开盘 | 恒指高开0.31% 医药CXO板块走强 药明康德(02359)涨近10%、中际旭创(03308)涨超9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656816586","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656816586?lang=zh_cn&edition=full","pubTime":"2026-08-04 09:34","pubTimestamp":1785807258,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月4日，恒生指数高开0.31%，报26090.98点；恒生科技指数涨0.30%，报4890.34点。医药CXO板块大幅走强，药明康德涨近10%，药明生物涨超3%，昭衍新药涨近6%，凯莱英涨超5%，泰格医药涨近4%。药明康德此前披露半年报，上半年营收288.97亿元同比增长38.93%，并全面上调全年业绩指引。光通信板块活跃，中际旭创涨超9%。云计算及AI应用板块走高，金山云涨超5%。受隔夜美股科技板块走强带动，港股今日延续高开。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475568.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09067","LU0417516902.SGD","LU0181495838.USD","LU0823426308.USD","300347","BK1141","03033","BK1122","LU0140636845.USD","LU0456827905.SGD","09088","02269","LU1794554557.SGD","BK1610","BK1583","03067","BK1149","82800","02837","03037","LU1242518931.SGD","BK1249","LU0823426480.USD","002821","06127","BK1521","LU2039709279.SGD","LU1720050803.USD","LU2125910500.SGD","513600","LU1046422090.SGD","LU1688375341.USD","HSTECH","LU0307460666.USD","LU0348825331.USD","02359","300308","07226","LU0052750758.USD","603259","HHImain","SG9999002463.SGD","LU0516422952.EUR","LU0516423091.SGD","LU2242644610.SGD","LU0320764599.SGD","LU0456846285.SGD","09115","LU0043850808.USD","LU0359202008.SGD","LU0359201612.USD","LU0708995583.HKD","LU0326950275.SGD","03417","03347","LU0327786744.USD","BK1191","03115","LU0348766576.USD","LU0417516738.SGD","06821","SG9999002562.SGD","03308","03088","LU1242518857.USD","LU0588546209.SGD","MCHmain","603127","03032","LU0819121731.USD","LU3063872942.SGD","LU0051755006.USD","LU0572944931.SGD","HSI","07200","03423","BK1576","02800","83115","LU0039217434.USD","LU0348735423.USD","BK1589","IE00B0JY6N72.USD","07552","KURE","LU0979878070.USD","BK1533","03419","LU0516422366.SGD","02833","LU1880383366.USD","LU2045819591.USD","07300","LU0856984785.SGD","WXXWY","LU0348767384.USD","07500","LU0516422440.USD","LU0516423174.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655333030","title":"医药外包概念整体回暖 昭衍新药（06127）涨4.51%、康龙化成（03759）涨3.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655333030","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655333030?lang=zh_cn&edition=full","pubTime":"2026-07-31 10:18","pubTimestamp":1785464310,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医药外包概念整体回暖，截止发稿，昭衍新药 涨4.51%，康龙化成涨3.10%，金斯瑞生物科技涨2.97%，凯莱英涨2.77%，药明生物涨2.75%，药明康德涨2.60%，泰格医药涨1.39%。26年至今国内创新药行业的长期结构性机会持续兑现，国内投融资持续改善，新药物形式赛道持续火热并进一步放量，该机构认为26年国内CRO/CDMO行业的新签订单及业绩会加速增长，带动CXO产业链进入新一轮发展阶段。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987205","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002463.SGD","LU0327786744.USD","LU1880383366.USD","LU0140636845.USD","LU1046422090.SGD","09939","LU0823426308.USD","HK0000306685.HKD","LU3063872942.SGD","LU0348766576.USD","LU0348825331.USD","300759","LU0516422366.SGD","LU1720050803.USD","LU0359202008.SGD","BK1141","LU0516423091.SGD","02359","LU0823426480.USD","LU0320764599.SGD","LU2045819591.USD","01548","LU0708995583.HKD","LU0181495838.USD","LU0051755006.USD","06821","KURE","LU0516422440.USD","LU0307460666.USD","LU0417516738.SGD","BK1574","LU0348735423.USD","03759","BK1589","LU0819121731.USD","HK0000306701.USD","159938","03347","BK1191","06127","BK1521","LU0588546209.SGD","LU0456827905.SGD","LU1242518931.SGD","02269","LU1242518857.USD","BK1610","LU0359201612.USD","603127","LU1794554557.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655827872","title":"昭衍新药：非人灵长类实验动物存栏属于公司经营核心运营数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2655827872","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655827872?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:12","pubTimestamp":1785402735,"startTime":"0","endTime":"0","summary":"非人灵长类实验动物存栏属于公司经营核心运营数据，涉及多方面的商业信息，同时，公司积极利用最先进的科学技术，持续统筹繁育能力的改进和建设，以争取持续响应客户研发项目的需求，相关情况请关注公司定期公告。由于非人灵长类实验动物的价格受多种不确定性因素影响，存在较大价值波动风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000026844.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","603127","BK1141","06127","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655217278","title":"7月30日昭衍新药跌8.85%，广发医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2655217278","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655217278?lang=zh_cn&edition=full","pubTime":"2026-07-30 16:33","pubTimestamp":1785400410,"startTime":"0","endTime":"0","summary":"证券之星消息，7月30日昭衍新药跌8.85%，收盘报40.05元，换手率8.81%，成交量55.29万手，成交额22.96亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共40家，其中持有数量最多的公募基金为广发基金的广发医疗保健股票A。广发医疗保健股票A目前规模为35.24亿元，最新净值1.8159，较上一交易日下跌0.53%，近一年下跌14.97%。广发医疗保健股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000025793.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603127","06127","BK0216","BK1576","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654072201","title":"7月28日昭衍新药跌8.31%，广发医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2654072201","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654072201?lang=zh_cn&edition=full","pubTime":"2026-07-28 16:36","pubTimestamp":1785227762,"startTime":"0","endTime":"0","summary":"证券之星消息，7月28日昭衍新药跌8.31%，收盘报45.57元，换手率11.05%，成交量69.38万手，成交额32.52亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共40家，其中持有数量最多的公募基金为广发基金的广发医疗保健股票A。广发医疗保健股票A目前规模为35.24亿元，最新净值1.8816，较上一交易日上涨2.5%，近一年下跌7.86%。广发医疗保健股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800026332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","BK1141","603127","06127","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654095486","title":"医药外包概念全线扬升 昭衍新药(06127)涨7.93% 机构指CXO景气进入中报业绩兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2654095486","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654095486?lang=zh_cn&edition=full","pubTime":"2026-07-27 10:17","pubTimestamp":1785118673,"startTime":"0","endTime":"0","summary":"消息面上，开源证券新近研究指出，7月以来，康龙化成、昭衍新药、美迪西和药康生物先后发布2026年H1业绩预增公告，从早研到临床前研究，CXO景气周期已逐步进入利润表兑现期。根据医药魔方，2026H1全球创新药一级市场共发生505起融资事件，同比增长6.1%，融资金额达到267.5亿美元，同比增长58.5%。2026H1中国相关交易数量及金额涨势迅猛，总金额达997亿美元。从6月初至今，CXO板块在业绩和订单的支撑下，率先于创新药反弹。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986787","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0043850808.USD","LU1242518931.SGD","LU0348767384.USD","CXO","BK1610","LU0348735423.USD","LU0823426308.USD","06821","06127","LU0417516738.SGD","603127","LU2242644610.SGD","01873","BK1589","03759","03347","KURE","159938","BK0216","01548","BK1574","HK0000320264.USD","LU0823426480.USD","LU3063872942.SGD","LU0588546209.SGD","02269","WX","LU2125910500.SGD","BK1161","LU1242518857.USD","LU0307460666.USD","LU0327786744.USD","LU0140636845.USD","LU0039217434.USD","LU0856984785.SGD","BK1583","LU0516423174.USD","LU1046422090.SGD","LU2039709279.SGD","BK1141","LU1880383366.USD","LU0516422440.USD","SG9999002562.SGD","09939","HK0000306685.HKD","BK1191","02359","LU0516422952.EUR","LU0359201612.USD","LU0348766576.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654095550","title":"异动快报：昭衍新药（603127）7月27日10点2分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2654095550","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654095550?lang=zh_cn&edition=full","pubTime":"2026-07-27 10:05","pubTimestamp":1785117935,"startTime":"0","endTime":"0","summary":"证券之星7月27日盘中消息，10点2分昭衍新药（603127）触及涨停板。其所属行业医疗服务目前上涨。领涨股为创新医疗。该股为创新药，医药，AI医疗概念热股，当日创新药概念上涨3.66%，医药概念上涨3.38%，AI医疗概念上涨3.12%。7月24日的资金流向数据方面，主力资金净流出1.74亿元，占总成交额6.71%，游资资金净流出1.2亿元，占总成交额4.61%，散户资金净流入2.94亿元，占总成交额11.32%。近5日资金流向一览见下表：昭衍新药主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700005153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06127","BK1141","BK0216","BK1576","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654052374","title":"每周股票复盘：昭衍新药（603127）完成263.63万股限制性股票授予","url":"https://stock-news.laohu8.com/highlight/detail?id=2654052374","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654052374?lang=zh_cn&edition=full","pubTime":"2026-07-26 01:08","pubTimestamp":1784999294,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，昭衍新药报收于45.26元，较上周的47.93元下跌5.57%。昭衍新药当前最新总市值339.16亿元，在医疗服务板块市值排名7/51，在两市A股市值排名555/5200。公司公告汇总昭衍新药完成2026年A股限制性股票激励计划授予登记，实际向238名激励对象授予263.6300万股限制性股票，授予价格为19.05元/股，认购资金总额为50,221,515.00元。股票来源于公司在二级市场回购的A股普通股，相关股份已完成性质变更，由无限售条件流通股转为有限售条件流通股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","06127","BK1141","603127","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653770707","title":"7月24日昭衍新药跌6.66%，广发医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653770707","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653770707?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:37","pubTimestamp":1784882276,"startTime":"0","endTime":"0","summary":"证券之星消息，7月24日昭衍新药跌6.66%，收盘报45.26元，换手率8.94%，成交量56.12万手，成交额25.97亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共40家，其中持有数量最多的公募基金为广发基金的广发医疗保健股票A。广发医疗保健股票A目前规模为35.24亿元，最新净值1.9034，较上一交易日上涨0.6%，近一年下跌7.51%。广发医疗保健股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400028586.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","BK1576","BK1141","06127","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653726691","title":"昭衍新药（603127）披露2026年A股限制性股票激励计划授予结果公告，7月23日股价上涨0.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653726691","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653726691?lang=zh_cn&edition=full","pubTime":"2026-07-23 22:10","pubTimestamp":1784815828,"startTime":"0","endTime":"0","summary":"截至2026年7月23日收盘，昭衍新药报收于48.49元，较前一交易日上涨0.89%，最新总市值为363.36亿元。近日，北京昭衍新药研究中心股份有限公司披露《2026年A股限制性股票激励计划授予结果公告》。公告显示，公司完成2026年A股限制性股票激励计划授予登记，登记日为2026年7月22日，实际授予238名激励对象263.6300万股，授予价格19.05元/股，股票来源为二级市场回购股份。激励成本合计约3,756.73万元，将在2026年至2029年期间分期摊销。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300047921.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603127","BK1141","BK0216","BK1576","06127","399300","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652821977","title":"昭衍新药（603127）披露完成股份性质变更暨2026年A股限制性股票激励计划实施进展，7月20日股价下跌1.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652821977","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652821977?lang=zh_cn&edition=full","pubTime":"2026-07-20 22:04","pubTimestamp":1784556262,"startTime":"0","endTime":"0","summary":"截至2026年7月20日收盘，昭衍新药报收于47.0元，较前一交易日下跌1.94%，最新总市值为352.19亿元。近日，昭衍新药发布《关于完成股份性质变更暨2026年A股限制性股票激励计划实施的进展公告》。公告显示，公司已完成2026年A股限制性股票激励计划授予登记，实际向238名激励对象授予263.6300万股限制性股票，授予价格为19.05元/股，认购款总计50,221,515.00元。股份来源为公司从二级市场回购的A股普通股股票，相关股份已由无限售条件流通股变更为有限售条件流通股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000039186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","BK1141","159982","399300","BK0216","06127","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652890218","title":"Barclays PLC增持昭衍新药(06127)约327.98万股 每股作价约24.25港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652890218","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652890218?lang=zh_cn&edition=full","pubTime":"2026-07-20 19:32","pubTimestamp":1784547178,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，7月15日，Barclays PLC增持昭衍新药327.982万股，每股作价24.2508港元，总金额约为7953.83万港元。增持后最新持股数目约为728.53万股，最新持股比例为6.12%。补充资料：Notifiable interest first occurred due to increase in Equity shares. BBPLCs interests in 2068664 shares long and short and BCSLs interests in 1295444 shares long and 773220 shares short as disclosed at box 22 pertain to an intragroup hedge between BBPLC and BCSL. Interests arising under the hedge are not double counted at BPLCs level.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469911.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","603127","06127","BK1141","BK1576","EWH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1786678241283,"stockEarnings":[{"period":"1week","weight":0.1219},{"period":"1month","weight":0.1278},{"period":"3month","weight":0.3027},{"period":"6month","weight":0.4436},{"period":"1year","weight":0.5235},{"period":"ytd","weight":0.4869}],"compareEarnings":[{"period":"1week","weight":0.0068},{"period":"1month","weight":-0.0101},{"period":"3month","weight":-0.0504},{"period":"6month","weight":-0.038},{"period":"1year","weight":0.0661},{"period":"ytd","weight":-0.0106}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京昭衍新药研究中心股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"0人","perCapita":"--","listingDate":"2017-08-25","address":"北京市大兴区北京经济技术开发区荣京东街甲5号","registeredCapital":"74934万元","survey":" 北京昭衍新药研究中心股份有限公司的主营业务是以药物非临床安全性评价服务为主的药物临床前研究服务和实验动物及附属产品的销售业务。公司的主要产品或服务是药物非临床研究服务、临床服务及其他、实验模型供应。公司同时具备中国NMPA、美国FDA、经合组织OECD、韩国MFDS、日本PMDA等GLP资质；2025年9月公司北京及太仓设施通过了OECD的GLP现场检查及复查。","listedPrice":12.51},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昭衍新药(603127)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昭衍新药(603127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昭衍新药,603127,昭衍新药股票,昭衍新药股票老虎,昭衍新药股票老虎国际,昭衍新药行情,昭衍新药股票行情,昭衍新药股价,昭衍新药股市,昭衍新药股票价格,昭衍新药股票交易,昭衍新药股票购买,昭衍新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昭衍新药(603127)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昭衍新药(603127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}